OBJECTIVE: To determine the antiproliferative activity of Rubus parvifolius L. (RP) extract, its medicinal serum and RP total saponins (RPTS) against K562 cells in vitro and in vivo. METHODS: Nude mice models bearing leukemia tumors were treated with different concentrations of RP extract. The size, weight and histopathological change of leukemic tumors were determined. Semi-solid agar culture and methylthiazolyl tetrazolium (MTT) assay were used to determine in vitro the inhibition of colony formation and proliferation of K562 cells respectively by different concentrations of RP medicinal serum and RPTS. RESULTS: RP extract had a tumor inhibition rate of 84.8% when administered to mice at a dose of 1.0 g/day of crude RP root equivalent. Semi-solid agar culture of K562 cells in the presence of 20% (v/v) of RP medicinal serum and 150 mg/L RPTS demonstrated a 50.8% and 100% inhibition of the colony forming unit (CFU)-K562, respectively. The same doses of RP medicinal serum and RPTS showed a proliferation inhibition of 31.4% and 86.3%, respectively against K562 cells in MTT assay. CONCLUSION: RP extract and RPTS show effective antiproliferative activity against myeloid leukemia cells in vitro and in vivo.
OBJECTIVE: To determine the antiproliferative activity of Rubus parvifolius L. (RP) extract, its medicinal serum and RP total saponins (RPTS) against K562 cells in vitro and in vivo. METHODS:Nude mice models bearing leukemia tumors were treated with different concentrations of RP extract. The size, weight and histopathological change of leukemic tumors were determined. Semi-solid agar culture and methylthiazolyl tetrazolium (MTT) assay were used to determine in vitro the inhibition of colony formation and proliferation of K562 cells respectively by different concentrations of RP medicinal serum and RPTS. RESULTS: RP extract had a tumor inhibition rate of 84.8% when administered to mice at a dose of 1.0 g/day of crude RP root equivalent. Semi-solid agar culture of K562 cells in the presence of 20% (v/v) of RP medicinal serum and 150 mg/L RPTS demonstrated a 50.8% and 100% inhibition of the colony forming unit (CFU)-K562, respectively. The same doses of RP medicinal serum and RPTS showed a proliferation inhibition of 31.4% and 86.3%, respectively against K562 cells in MTT assay. CONCLUSION: RP extract and RPTS show effective antiproliferative activity against myeloid leukemia cells in vitro and in vivo.
Authors: David M Lucas; Ryan B Edwards; Gerard Lozanski; Derek A West; Jungook D Shin; Melissa A Vargo; Melanie E Davis; Darlene M Rozewski; Amy J Johnson; Bao-Ning Su; Virginia M Goettl; Nyla A Heerema; Thomas S Lin; Amy Lehman; Xiaoli Zhang; David Jarjoura; David J Newman; John C Byrd; A Douglas Kinghorn; Michael R Grever Journal: Blood Date: 2009-02-03 Impact factor: 22.113